Acrivon Therapeutics Inc (ACRV) Stock Price, Quote & News

Company Profile

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 207 8979

Website: acrivon.com

Address:

480 Arsenal Way, Suite 100, Watertown, United States

Dou_said_it Mar. 16 at 7:00 PM

$ACRV The next months ( from now to mid 2026) will be Green for ACRV

1 · Reply

nmarrone2207 Mar. 16 at 6:49 PM

$ACRV now we're cooking !

0 · Reply

Ramanda87 Mar. 12 at 3:57 PM

$ACRV forecasts from $8 to $19 and everywhere in between and this thing has been a terd for sometime now… thoughts?

2 · Reply

Dou_said_it Mar. 10 at 1:37 PM

$ACRV Goooood, hope Some news soon

0 · Reply

Funktrade Mar. 6 at 2:57 PM

$ACRV OMG . Such bullshit 😡😡😡😡

1 · Reply

Jmyoob Mar. 5 at 4:24 PM

$ACRV what happend today?

0 · Reply

PreGigs Mar. 5 at 3:03 PM

$ACRV 6'ish and I go for Christmas in Japan this year!

0 · Reply

DwigtMcDichael Mar. 3 at 7:53 PM

$ACRV bought the dip in Jan- looking for $6+

0 · Reply

lanetta3 Mar. 3 at 7:08 PM

$ACRV what’s the target for this week?

0 · Reply

Orlandotrader Mar. 3 at 6:12 PM

$ACRV New Position.

0 · Reply

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 8:00 AM EST - 21 days ago

Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

Feb 18, 2026, 8:00 AM EST - 26 days ago

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

Jan 23, 2026, 8:11 AM EST - 7 weeks ago

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

Jan 8, 2026, 2:02 PM EST - 2 months ago

Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls

Jan 8, 2026, 7:30 AM EST - 2 months ago

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Jan 6, 2026, 7:30 AM EST - 2 months ago

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Dec 17, 2025, 9:34 AM EST - 3 months ago

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Nov 13, 2025, 4:10 PM EST - 4 months ago

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 22, 2025, 4:15 PM EDT - 5 months ago

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

Oct 1, 2025, 4:30 PM EDT - 5 months ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2025, 4:15 PM EDT - 7 months ago

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 4:10 PM EDT - 10 months ago

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Apr 25, 2025, 8:00 AM EDT - 11 months ago

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Apr 7, 2025, 4:05 PM EDT - 1 year ago

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Mar 27, 2025, 5:44 PM EDT - 1 year ago

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Dec 12, 2024, 3:25 PM EST - 1 year ago

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Sep 18, 2024, 10:11 AM EDT - 1 year ago

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Sep 14, 2024, 3:10 AM EDT - 1 year ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Jun 13, 2024, 2:00 PM EDT - 1 year ago

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?

May 29, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 24, 2024, 7:16 PM EDT - 2 years ago

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Apr 24, 2024, 4:01 PM EDT - 2 years ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Apr 16, 2024, 8:01 PM EDT - 2 years ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Apr 9, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Apr 3, 2024, 3:07 AM EDT - 2 years ago

What To Buy After You Sell The Russell 2000

AVUV IJR IWM IWN MLYS NXT SKWD

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 5, 2024, 4:30 PM EST - 2 years ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Feb 27, 2024, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 12, 2024, 4:00 PM EST - 2 years ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 21, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Nov 9, 2023, 8:01 AM EST - 2 years ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 19, 2023, 4:32 PM EDT - 2 years ago

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Sep 5, 2023, 4:05 PM EDT - 2 years ago

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jun 22, 2023, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Mar 28, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Mar 26, 2023, 9:53 AM EDT - 3 years ago

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Mar 6, 2023, 8:00 AM EST - 3 years ago

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Dou_said_it Mar. 16 at 7:00 PM

$ACRV The next months ( from now to mid 2026) will be Green for ACRV

1 · Reply

nmarrone2207 Mar. 16 at 6:49 PM

$ACRV now we're cooking !

0 · Reply

Ramanda87 Mar. 12 at 3:57 PM

$ACRV forecasts from $8 to $19 and everywhere in between and this thing has been a terd for sometime now… thoughts?

2 · Reply

Dou_said_it Mar. 10 at 1:37 PM

$ACRV Goooood, hope Some news soon

0 · Reply

Funktrade Mar. 6 at 2:57 PM

$ACRV OMG . Such bullshit 😡😡😡😡

1 · Reply

Jmyoob Mar. 5 at 4:24 PM

$ACRV what happend today?

0 · Reply

PreGigs Mar. 5 at 3:03 PM

$ACRV 6'ish and I go for Christmas in Japan this year!

0 · Reply

DwigtMcDichael Mar. 3 at 7:53 PM

$ACRV bought the dip in Jan- looking for $6+

0 · Reply

lanetta3 Mar. 3 at 7:08 PM

$ACRV what’s the target for this week?

0 · Reply

Orlandotrader Mar. 3 at 6:12 PM

$ACRV New Position.

0 · Reply

Investman10 Mar. 3 at 4:58 PM

$ACRV If we’re rising strongly in a high-volatility environment, imagine how much we’ll rise when the overall market sentiment improves.

0 · Reply

Funktrade Mar. 3 at 2:32 PM

$ACRV THIS FUCKING SUCKS . Down 40% in 2 months. 😡😡😡😡😡😡😡

0 · Reply

open_outcry Mar. 3 at 12:26 AM

$ACRV was just listening to part of the fireside chat webcast from earlier today. one of the questions the moderator asked PB-J was what investors might be missing with respect to ACR 368 (essentially acknowledging that the SP has behaved poorly since the release of the latest clinical trial data on ORR). PB-J's answer was that serous subtype endometrial cancer accounts for nearly 50% of all endometrial cancer deaths, yet there are very limited options for treating it, and that leading experts in the field are very enthusiastic about the trial results. i had to use google search to find # of annual endometrial cancer deaths and translate that ~50% into real numbers. i think in time $ACRV will tighten up their elevator pitch and investors will catch on, so this remains a long-term hold for me.

2 · Reply

open_outcry Mar. 2 at 11:56 PM

$ACRV https://www.stocktitan.net/sec-filings/ACRV/8-k-acrivon-therapeutics-inc-reports-material-event-d46d17e38006.html seems positive...

0 · Reply

Dylberts Mar. 2 at 4:51 PM

Reaching out to $ACRV's investment relations in hopes of facilitating a positive discussion. While I still believe in the future here, the continual volatility on good news leaves me craving more insight and reassurance. Will follow up with any important info later on—

0 · Reply

R0MER0 Mar. 2 at 1:02 PM

$ACRV In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Acrivon Therapeutics, Inc., with a price target of $8.00. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential According to TipRanks, Tenthoff is a 4-star analyst with an average return of 5.7% and a 40.66% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Moderna, Karyopharm Therapeutics, and Arrowhead Pharmaceuticals. In a report released on February 27, H.C. Wainwright also maintained a Buy rating on the stock with a $19.00 price target.

0 · Reply

R0MER0 Mar. 2 at 1:19 AM

$ACRV add a couple more

0 · Reply

focafoca99 Mar. 1 at 8:18 AM

$ACRV reports 39% ORR in endometrial cancer and still drops 18%? Market clearly expected more.

1 · Reply

Trinity031983 Feb. 28 at 5:51 PM

$ACRV https://tipranks.onelink.me/WJho/997rnvww

0 · Reply

Trinity031983 Feb. 28 at 5:50 PM

$ACRV https://tipranks.onelink.me/WJho/0pf0wdcg

0 · Reply

Dylberts Feb. 28 at 3:11 AM

Ouch, that opening bell sell off of $ACRV hurt after a 2 Day rally towards recovery... Could be a case of voltatile profit taking, price manipulation, and or indecisiveness about the recent good news they just reported. In my opinion it *was* all good news though, showing further promising results. At this current price I believe $ACRV is still severely undervalued. Only wish I had more liquid funds to allocate here right now... I believe more news is expected in early March, so hopefully sentiment will shift! Long term outlook is still very bullish, low sharing borrowing, FDA approval pending, and plenty of slush fund left before needing to raise more. Don't panic by giving the bears their shares! I'm down $14K here just today, but it's a small price to pay for when i'm up 5-10x that.

0 · Reply

Dani_G_German Feb. 27 at 9:31 PM

$ACRV I added

1 · Reply

Market Cap	51.12M
Revenue (ttm)	0.00
Net Income (ttm)	-80.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	817,700
Avg Vol	1,997,860
Day's Range	N/A - N/A
Shares Out	31.56M
Stochastic %K	72%
Beta	1.79
Analysts	Strong Sell
Price Target	$11.50